Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains

Two genes recently associated with glycopeptide intermediate resistance in Staphylococcus aureus (GISA) are mprF and tcaA, with inactivation causing shifts in vancomycin resistance. This study reveals that expression levels of both genes are similar in groups of clinical GISA, heteroGISA and glycope...

Full description

Saved in:
Bibliographic Details
Published inBiochimica et biophysica acta Vol. 1726; no. 3; pp. 326 - 327
Main Authors Wootton, M., Macgowan, A.P., Walsh, T.R.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 30.11.2005
Subjects
Aminoacyltransferases
Bacterial Proteins - genetics
Bacterial Proteins - metabolism
Clinical isolate
Gene Expression
Glycopeptide-intermediate resistance
Mechanism of resistance
Staphylococcus aureus
Staphylococcus aureus - drug effects
Staphylococcus aureus - isolation & purification
Staphylococcus aureus - metabolism
Vancomycin Resistance
Glycopeptide-intermediate resistance
Mechanism of resistance
Gene expression
Clinical isolate
Staphylococcus aureus
Online AccessGet full text

Cover

More Information
Summary:Two genes recently associated with glycopeptide intermediate resistance in Staphylococcus aureus (GISA) are mprF and tcaA, with inactivation causing shifts in vancomycin resistance. This study reveals that expression levels of both genes are similar in groups of clinical GISA, heteroGISA and glycopeptide susceptible strains, suggesting no association with clinical isolates.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0304-4165
0006-3002
1872-8006
DOI:10.1016/j.bbagen.2005.09.002